Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

, ABT

Abbott

$40.59

-0.2 (-0.49%)

08:01
10/18/16
10/18
08:01
10/18/16
08:01

St. Jude Medical, Abbott to sell part of vascular closure business to Terumo

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

ABT

Abbott

$40.59

-0.2 (-0.49%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$77.66

-0.32 (-0.41%)

10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
ABT Abbott
$40.59

-0.2 (-0.49%)

09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

TODAY'S FREE FLY STORIES

MO

Altria Group

$73.65

0.68 (0.93%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Earnings
Altria Group backs FY17 adjusted EPS view $3.26-$3.32, consensus $3.31 »

Altria reaffirms its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$73.65

0.68 (0.93%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Hot Stocks
Breaking Hot Stocks news story on Altria Group »

Altria Group reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:56
02/22/17
02/22
07:56
02/22/17
07:56
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Restaurant Brands…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Argos Therapeutics »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

GS

Goldman Sachs

$251.76

1.38 (0.55%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Initiation
Goldman Sachs initiated  »

Goldman Sachs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

RDS.A

Royal Dutch Shell

$52.49

0.29 (0.56%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ACRX

AcelRx

$3.15

0.05 (1.61%)

, CBM

Cambrex

$54.90

0.55 (1.01%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

ACRX

AcelRx

$3.15

0.05 (1.61%)

CBM

Cambrex

$54.90

0.55 (1.01%)

CRIS

Curis

$2.66

-0.02 (-0.75%)

ESPR

Esperion

$24.42

-0.58 (-2.32%)

DVAX

Dynavax

$3.95

-0.05 (-1.25%)

FLXN

Flexion

$19.66

0.43 (2.24%)

GILD

Gilead

$69.29

-0.56 (-0.80%)

CURE

Curative Health Services Inc

$33.80

0.45 (1.35%)

PCRX

Pacira

$44.15

0.45 (1.03%)

NVDQ

Novadaq

$6.76

0.17 (2.58%)

AXON

Axovant Sciences

$12.11

-0.03 (-0.25%)

TSRO

TESARO

$190.27

-0.09 (-0.05%)

EGRX

Eagle Pharmaceuticals

$73.59

-0.53 (-0.72%)

LPNT

LifePoint

$65.15

1.25 (1.96%)

PRTA

Prothena

$55.00

-0.22 (-0.40%)

ABEO

Abeona Therapeutics

$5.25

-0.75 (-12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 06

    Mar

  • 17

    Mar

  • 21

    Mar

  • 01

    Apr

  • 27

    Apr

  • 30

    Jun

  • 06

    Oct

MS

Morgan Stanley

$46.56

0.41 (0.89%)

07:54
02/22/17
02/22
07:54
02/22/17
07:54
Initiation
Morgan Stanley initiated  »

Morgan Stanley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
02/22/17
02/22
07:53
02/22/17
07:53
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$76.10

2 (2.70%)

07:52
02/22/17
02/22
07:52
02/22/17
07:52
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

SOHO

Sotherly Hotels

$7.04

-0.4 (-5.38%)

07:51
02/22/17
02/22
07:51
02/22/17
07:51
Recommendations
Sotherly Hotels analyst commentary  »

Sotherly Hotels can still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$45.60

-0.02 (-0.04%)

07:49
02/22/17
02/22
07:49
02/22/17
07:49
Initiation
Glaukos initiated  »

Glaukos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DBD

Diebold

$29.70

-0.4 (-1.33%)

07:48
02/22/17
02/22
07:48
02/22/17
07:48
Initiation
Diebold initiated  »

Diebold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FSLR

First Solar

$36.62

1.78 (5.11%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$126.34

1.07 (0.85%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Hot Stocks
Aetna announces $3.3B accelerated share repurchase »

Aetna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Conference/Events
CFA Society of Washington, D.C. to hold a luncheon discussion »

The CFA Society of…

CSCO

Cisco

$34.13

0.39 (1.16%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Cisco analyst commentary  »

Cisco at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

M

Macy's

$32.29

-0.01 (-0.03%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Macy's analyst commentary  »

Macy's risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$111.07

3.84 (3.58%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Initiation
NVIDIA initiated  »

NVIDIA initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

EYEG

EyeGate

$3.70

2.0601 (125.62%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files $3.29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$66.94

1.02 (1.55%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Hot Stocks
Welltower enters into strategic collaboration with Johns Hopkins Medicine »

Welltower announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 01

    Mar

HD

Home Depot

$145.02

2.02 (1.41%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Recommendations
Home Depot analyst commentary  »

Home Depot guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

AMD

AMD

$14.00

0.87 (6.63%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Initiation
AMD initiated  »

AMD initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.